NCT05428930View on ClinicalTrials.gov

Safety and Efficacy of CKDB-501B in Subjects With Moderate-to-severe Glabellar Lines

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 22, 2022

Primary Completion Date

October 25, 2022

Study Completion Date

October 25, 2022

Conditions
Glabellar Lines
Interventions
DRUG

CKDB-501B

Intramuscular injection CKDB-501B

DRUG

Botox®50U

Intramuscular injection Botox®50U

Trial Locations (1)

Unknown

Chung-Ang University Hospital, Seoul

Sponsors
All Listed Sponsors
lead

CKD Bio Corporation

INDUSTRY

NCT05428930 - Safety and Efficacy of CKDB-501B in Subjects With Moderate-to-severe Glabellar Lines | Biotech Hunter | Biotech Hunter